Abcellera Biologics Inc
NASDAQ:ABCL
Cash Flow Statement
Cash Flow Statement
Abcellera Biologics Inc
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||
| Net Income |
0
|
119
|
236
|
229
|
211
|
154
|
205
|
200
|
248
|
159
|
(50)
|
(74)
|
(129)
|
(146)
|
(147)
|
(153)
|
(176)
|
(163)
|
(168)
|
(166)
|
(172)
|
|
| Depreciation & Amortization |
3
|
5
|
8
|
10
|
13
|
15
|
15
|
17
|
18
|
28
|
30
|
30
|
31
|
24
|
24
|
55
|
91
|
91
|
91
|
60
|
24
|
|
| Change in Deffered Taxes |
0
|
2
|
3
|
3
|
(1)
|
(2)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
5
|
8
|
14
|
20
|
26
|
31
|
38
|
41
|
45
|
49
|
53
|
57
|
61
|
64
|
66
|
68
|
69
|
68
|
65
|
61
|
58
|
|
| Other Non-Cash Items |
5
|
14
|
19
|
26
|
33
|
37
|
44
|
48
|
56
|
63
|
64
|
68
|
67
|
63
|
71
|
32
|
2
|
(11)
|
(13)
|
22
|
53
|
|
| Change in Working Capital |
14
|
(117)
|
(134)
|
(4)
|
7
|
42
|
(26)
|
88
|
(94)
|
30
|
92
|
(142)
|
41
|
13
|
9
|
(26)
|
(39)
|
(26)
|
12
|
3
|
(10)
|
|
| Cash from Operating Activities |
22
N/A
|
23
+4%
|
132
+482%
|
265
+100%
|
263
-1%
|
245
-7%
|
235
-4%
|
351
+49%
|
230
-34%
|
277
+21%
|
133
-52%
|
(120)
N/A
|
7
N/A
|
(44)
N/A
|
(41)
+5%
|
(91)
-120%
|
(120)
-32%
|
(109)
+10%
|
(78)
+28%
|
(81)
-3%
|
(105)
-29%
|
|
| Investing Cash Flow | ||||||||||||||||||||||
| Capital Expenditures |
(14)
|
(15)
|
(18)
|
(46)
|
(51)
|
(59)
|
(69)
|
(64)
|
(70)
|
(73)
|
(73)
|
(69)
|
(76)
|
(78)
|
(87)
|
(80)
|
(77)
|
(78)
|
(65)
|
(58)
|
(49)
|
|
| Other Items |
2
|
(105)
|
(117)
|
(128)
|
(389)
|
(274)
|
(274)
|
(261)
|
(267)
|
(280)
|
(403)
|
(414)
|
(139)
|
(144)
|
45
|
124
|
139
|
200
|
164
|
74
|
97
|
|
| Cash from Investing Activities |
(12)
N/A
|
(120)
-882%
|
(136)
-13%
|
(174)
-28%
|
(439)
-153%
|
(332)
+24%
|
(343)
-3%
|
(324)
+5%
|
(337)
-4%
|
(353)
-5%
|
(476)
-35%
|
(483)
-2%
|
(214)
+56%
|
(221)
-3%
|
(42)
+81%
|
45
N/A
|
61
+37%
|
121
+98%
|
99
-18%
|
16
-84%
|
48
+211%
|
|
| Financing Cash Flow | ||||||||||||||||||||||
| Net Issuance of Common Stock |
76
|
599
|
599
|
526
|
526
|
5
|
6
|
5
|
4
|
3
|
1
|
1
|
8
|
12
|
12
|
12
|
6
|
13
|
19
|
24
|
31
|
|
| Net Issuance of Debt |
(2)
|
85
|
84
|
71
|
86
|
(1)
|
1
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other |
0
|
0
|
0
|
(8)
|
(8)
|
(8)
|
(13)
|
(4)
|
(4)
|
(4)
|
0
|
(1)
|
(1)
|
(1)
|
2
|
4
|
7
|
(1)
|
(3)
|
(14)
|
(17)
|
|
| Cash from Financing Activities |
74
N/A
|
684
+824%
|
682
0%
|
589
-14%
|
604
+3%
|
(4)
N/A
|
(6)
-41%
|
1
N/A
|
(0)
N/A
|
(2)
-700%
|
1
N/A
|
0
-60%
|
7
+1 650%
|
10
+48%
|
14
+32%
|
16
+16%
|
12
-22%
|
13
+3%
|
16
+25%
|
10
-38%
|
14
+43%
|
|
| Change in Cash | ||||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(11)
|
(10)
|
(10)
|
(8)
|
(0)
|
1
|
0
|
(1)
|
1
|
(3)
|
(1)
|
(0)
|
(1)
|
|
| Net Change in Cash |
84
N/A
|
587
+601%
|
678
+16%
|
679
+0%
|
427
-37%
|
(93)
N/A
|
(114)
-23%
|
25
N/A
|
(118)
N/A
|
(86)
+27%
|
(351)
-307%
|
(610)
-74%
|
(200)
+67%
|
(254)
-27%
|
(69)
+73%
|
(31)
+55%
|
(46)
-45%
|
23
N/A
|
36
+55%
|
(56)
N/A
|
(43)
+22%
|
|
| Free Cash Flow | ||||||||||||||||||||||
| Free Cash Flow |
8
N/A
|
8
-1%
|
114
+1 324%
|
219
+92%
|
212
-3%
|
186
-12%
|
166
-11%
|
287
+73%
|
160
-44%
|
205
+28%
|
60
-71%
|
(189)
N/A
|
(69)
+64%
|
(121)
-76%
|
(128)
-6%
|
(171)
-33%
|
(197)
-15%
|
(187)
+5%
|
(143)
+23%
|
(139)
+3%
|
(153)
-10%
|
|